Table 2.
Nasal Symptom Scale scores and sneeze counts during late response phase
| Comparison | Measure | Hours after Nasal Allergen Challenge |
Treatment | Mean | N | SD | t | P (1-tailed) | |
| Loratadine- Placebo |
Nasal Symptoms Score |
2 | Loratadine | 5.1 | 18 | 3.5 | -1.10 | 0.143 | |
| Placebo | 5.9 | 18 | 3.1 | ||||||
| 4 | Loratadine | 4.1 | 18 | 3.4 | -1.43 | 0.086 | # | ||
| Placebo | 5.1 | 18 | 3.1 | ||||||
| 6 | Loratadine | 3.2 | 18 | 2.8 | -2.57 | 0.010 | ** | ||
| Placebo | 4.4 | 18 | 3.6 | ||||||
| 8 | Loratadine | 3.1 | 18 | 2.6 | -1.05 | 0.153 | |||
| Placebo | 3.8 | 18 | 3.4 | ||||||
| AUC | Loratadine | 15.5 | 18 | 10.7 | -1.82 | 0.044 | * | ||
| Placebo | 19.3 | 18 | 12.6 | ||||||
| Sneeze count | 2 | Loratadine | 2.2 | 17 | 3.0 | -1.25 | 0.114 | ||
| Placebo | 3.8 | 17 | 5.5 | ||||||
| 4 | Loratadine | 2.6 | 17 | 4.0 | -0.52 | 0.306 | |||
| Placebo | 3.2 | 17 | 4.5 | ||||||
| 6 | Loratadine | 1.4 | 17 | 2.3 | -2.22 | 0.021 | * | ||
| Placebo | 3.6 | 17 | 5.8 | ||||||
| 8 | Loratadine | 1.2 | 17 | 1.6 | -1.89 | 0.038 | * | ||
| Placebo | 2.7 | 17 | 3.8 | ||||||
| AUC | Loratadine | 7.5 | 17 | 7.8 | -1.79 | 0.047 | * | ||
| Placebo | 13.2 | 17 | 17.7 | ||||||
| Placebo-CBP | Nasal Symptoms Score |
2 | Placebo | 5.8 | 17 | 3.1 | 1.39 | 0.091 | # |
| CBP | 4.7 | 17 | 2.3 | ||||||
| 4 | Placebo | 4.9 | 17 | 3.1 | 1.71 | 0.053 | # | ||
| CBP | 3.6 | 17 | 2.3 | ||||||
| 6 | Placebo | 4.2 | 17 | 3.5 | 2.74 | 0.007 | ** | ||
| CBP | 2.4 | 17 | 2.4 | ||||||
| 8 | Placebo | 3.5 | 17 | 3.3 | 0.90 | 0.190 | |||
| CBP | 2.8 | 17 | 2.6 | ||||||
| AUC | Placebo | 18.4 | 17 | 12.4 | 1.86 | 0.041 | * | ||
| CBP | 13.6 | 17 | 8.0 | ||||||
| Sneeze count | 2 | Placebo | 3.2 | 17 | 5.2 | 1.57 | 0.068 | # | |
| CBP | 1.2 | 17 | 1.6 | ||||||
| 4 | Placebo | 2.7 | 17 | 4.4 | 1.72 | 0.052 | # | ||
| CBP | 1.2 | 17 | 1.9 | ||||||
| 6 | Placebo | 3.4 | 17 | 5.8 | 1.93 | 0.036 | * | ||
| CBP | 0.7 | 17 | 1.0 | ||||||
| 8 | Placebo | 2.3 | 17 | 3.7 | 0.90 | 0.191 | |||
| CBP | 1.5 | 17 | 2.3 | ||||||
| AUC | Placebo | 11.5 | 17 | 17.2 | 1.76 | 0.049 | * | ||
| CBP | 4.6 | 17 | 3.9 | ||||||
| Loratadine- CBP |
Nasal Symptoms Score |
2 | Loratadine | 4.8 | 17 | 3.4 | 0.14 | 0.447 | |
| CBP | 4.7 | 17 | 2.3 | ||||||
| 4 | Loratadine | 3.9 | 17 | 3.4 | 0.28 | 0.393 | |||
| CBP | 3.6 | 17 | 2.3 | ||||||
| 6 | Loratadine | 3.1 | 17 | 2.8 | 1.43 | 0.086 | # | ||
| CBP | 2.4 | 17 | 2.4 | ||||||
| 8 | Loratadine | 2.9 | 17 | 2.6 | 0.20 | 0.421 | |||
| CBP | 2.8 | 17 | 2.6 | ||||||
| AUC | Loratadine | 14.7 | 17 | 10.5 | 0.51 | 0.308 | |||
| CBP | 13.6 | 17 | 8.0 | ||||||
| Sneeze count | 2 | Loratadine | 1.8 | 16 | 2.6 | 0.88 | 0.197 | ||
| CBP | 1.3 | 16 | 1.6 | ||||||
| 4 | Loratadine | 2.4 | 16 | 4.0 | 1.09 | 0.145 | |||
| CBP | 1.3 | 16 | 1.9 | ||||||
| 6 | Loratadine | 1.3 | 16 | 2.4 | 1.07 | 0.151 | |||
| CBP | 0.7 | 16 | 1.0 | ||||||
| 8 | Loratadine | 1.1 | 16 | 1.5 | -0.55 | 0.295 | |||
| CBP | 1.4 | 16 | 2.3 | ||||||
| AUC | Loratadine | 6.6 | 16 | 7.1 | 1.18 | 0.128 | |||
| CBP | 4.7 | 16 | 4.1 |
# P < 0.10, * P < 0.05, ** P ≤ 0.01